Company Search:
Advanced Search
Sponsored Links
Halozyme Therapeutics, Inc. Company Snapshot
Halozyme Therapeutics, Inc. operates within the Biological products exc. diagnostic sector. In addition to historical fundamental analyses, the complete report available to purchase compares Halozyme Therapeutics with three other companies in this sector in the United States: 10X Genomics Inc (2018 sales of $146.31 million of which 100% was LABORATORY ANALYTICAL INSTRUMENTS), Intrexon Corp ($160.57 million of which 100% was Synthetic Biology), and Moderna Inc ($135.07 million of which 100% was Pharmaceutical).

Sales Analysis. During the year ended December of 2018, sales at Halozyme Therapeutics were $151.86 million. This is a sharp decrease of 52.0% versus 2017, when the company's sales were $316.61 million.
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Halozyme Therapeutics, Inc.
  Stock Performance Chart for Halozyme Therapeutics, Inc.
  Stock Data: Recent Stock Performance:
  Current Price (12/6/2019): 19.16
(Figures in U.S. Dollars)
1 Week -1.2%   13 Weeks 13.6%  
4 Weeks 20.3%   52 Weeks 26.7%  
Halozyme Therapeutics, Inc. Key Data:
  Ticker: HALO Country: United States
  Exchanges: NAS Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Biological Products Exc. Diagnostic
  2018 Sales 151,862,000
(Year Ending Jan 2019).
Employees: 281
  Currency: U.S. Dollars Market Cap: 2,806,116,120
  Fiscal Yr Ends: December Shares Outstanding: 146,457,000
  Share Type: Common Closely Held Shares: 16,044,023
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.